On September 2nd, China published the 2018 list of the top 500 Chinese enterprises, seen as an indicator of performance amid a context of steady economic growth.

With an annual operating revenue of 102 billion yuan, GPHL ranked 165th this year, up six places from last year’s position 171st, and ranked 68th among China’s top 500 manufacturing enterprises, an improvement on last year’s 73 spot.  

The list, jointly released by the China Enterprise Confederation (CEC) and China Enterprise Directors Association, showed the top 500 enterprises have generated total revenues of 71.17 trillion yuan (10.44 trillion U.S. dollars) in 2017, up 11.2 percent from the year before.

GPHL’s total sales revenue exceeded 100 billion yuan in 2017. And it has ranked as the country’s top pharmaceuticals manufacturer for seven consecutive years.

Li Chuyuan delivering a speech at the conference.

Li Chuyuan said, “GPHL’s sales revenue in 2018 is expected to be 10,000 times than that of Baiyunshan pharmaceutical factory’s in 1980. We will not rest on our past achievements, and hope to improve on the quality and effectiveness of our development in coming years.”

According to Li Chuyuan, there are four driving forces for GPHL’s development: targeting consumer demands; seizing the opportunities for industrial development; emphasizing the importance of  R&D and establishing a talent pool.

Reported by Jasmine Yin, Rebecca Tao

Edited by Wing Zhang, Simon Haywood